Everolimus-Eluting Versus Biolimus-Eluting Stents With Biodegradable Polymers in Unselected Patients Undergoing Percutaneous Coronary Intervention: A Randomized Noninferiority Trial With 1-Year Follow-Up (SORT OUT VIII Trial).

Michael Maeng,Evald Høj Christiansen,Bent Raungaard,Johnny Kahlert,Christian Juhl Terkelsen,Steen Dalby Kristensen,Steen Carstensen,Jens Aarøe,Svend Eggert Jensen,Anton Boel Villadsen,Jens Flensted Lassen,Troels Thim,Ashkan Eftekhari,Karsten Tange Veien,Knud Nørregaard Hansen,Anders Junker,Hans Erik Bøtker,Lisette Okkels Jensen

JACC: Cardiovascular Interventions（2019）

Cited 25|Views97

No score

Abstract

At 1-year follow-up, the EES was found to be noninferior to the BES with respect to target lesion failure. (Everolimus-eluting SYNERGY Stent Versus Biolimus-Eluting Biomatrix NeoFlex Stent-SORT-OUT VIII; NCT02093845).

Translated text

Key words

biodegradable polymer,biolimus,drug-eluting stent(s),everolimus,percutaneous coronary intervention,randomized clinical trial

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined